Albumin nanoscience: homing nanotechnology enabling targeted drug delivery and therapy
Authors:
- 8 January 2020
- journal article
- review article
- Published by Springer Nature in Archives of Pharmacal Research
- Vol. 43 (1) , 118-133
Abstract
Albumin is a biocompatible, non-immunogenic and versatile drug carrier system. It has been widely used to extend the half-life, enhance stability, provide protection from degradation and allow specific targeting of therapeutic agents to various disease states. Understanding the role of albumin as a drug delivery and distribution system has increased remarkably in the recent years from the development of albumin-binding prodrugs to albumin as a drug carrier system. The extraordinary surface property of albumin makes it possible to bind various endogenous and exogenous molecules. This review succinctly deals with several albumin-drug conjugates and nanoparticles along with their preparation techniques and focuses on surface-modified albumin and targeting of albumin formulation to specific organs and tissues. It also summarizes research efforts on albumin nanoparticles used for delivering drugs to tumor cells and describes their role in permeation through tumor vasculature and in receptor mediated endocytosis, which is also described in this review. The versatility of albumin and ease of preparation makes it a suitable drug carrier system, swhich is the major objective of this review.Keywords
Funding Information
- National Research Foundation of Korea (NRF-2016R1D1A1B01015369, NRF-2016R1A6A1A03011325)
This publication has 119 references indexed in Scilit:
- Innovative coagulation factors: albumin fusion technology and recombinant single-chain factor VIIIThrombosis Research, 2013
- Human serum albumin (HSA) nanoparticles stabilized with intermolecular disulfide bondsChemical Communications, 2013
- Uptake Mechanism of ApoE-Modified Nanoparticles on Brain Capillary Endothelial Cells as a Blood-Brain Barrier ModelPLOS ONE, 2012
- Targeted Albumin-Based Nanoparticles for Delivery of Amphipathic DrugsBioconjugate Chemistry, 2011
- In vivo evaluation of a novel albumin-binding prodrug of doxorubicin in an orthotopic mouse model of prostate cancer (LNCaP)Prostate Cancer and Prostatic Diseases, 2010
- Enhanced drug targeting by attachment of an anti αv integrin antibody to doxorubicin loaded human serum albumin nanoparticlesBiomaterials, 2010
- Albumin as a drug carrier: Design of prodrugs, drug conjugates and nanoparticlesJournal of Controlled Release, 2008
- The tumor microenvironment and its role in promoting tumor growthOncogene, 2008
- Targeting 15d-Prostaglandin J2 to Hepatic Stellate Cells: Two Options EvaluatedPharmaceutical Research, 2007
- Covalent Linkage of Apolipoprotein E to Albumin Nanoparticles Strongly Enhances Drug Transport into the BrainThe Journal of Pharmacology and Experimental Therapeutics, 2006